Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2020 | ETOP/IFCT 4-12 STIMULI updates from ESMO 2020

Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, discusses the results from the ETOP/IFCT 4-12 STIMULI trial (NCT02046733). The trial investigated the consolidation of ipilimumab and nivolumab in limited-stage small-cell lung cancer compared with standard chemo-radiotherapy treatment alone and found no progression-free survival or overall survival advantage. Prof. Popat proposes that this may be due to high discontinuation rates resulting from the incidence of Grade 3+ immune-related adverse events. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.